Research programme: anti-Flightless I antibody - AbRegen

Drug Profile

Research programme: anti-Flightless I antibody - AbRegen

Alternative Names: Anti-Flightless I antibody - AbRegen

Latest Information Update: 22 Jun 2017

Price : $50

At a glance

  • Originator University of South Australia
  • Developer AbRegen
  • Class Antibodies; Skin disorder therapies
  • Mechanism of Action FLII protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Epidermolysis bullosa

Most Recent Events

  • 22 Jun 2017 AbRegen plans a phase II trial for Epidermolysis in Australia (AbRegen pipeline, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top